In Brief: Anika Research
This article was originally published in The Gray Sheet
Anika Research: Files CE mark registration for European marketing approval of its Orthovisc "ultra-pure" high molecular weight hyaluronic acid product, which is "used to relieve pain, reduce inflammation and improve joint function in patients with osteoarthritis," the firm states. Anika recently initiated a Phase III double-blind, placebo-controlled trial of the product in the U.S. for treating osteoarthritis of the knee. The study is expected to include 220 patients...
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.